SAILIFENSE8 August 2025

Sai Life Sciences Limited has informed the Exchange about Investor Presentation

Sai Life Sciences Limited

08 August 2025

To National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 NSE Scrip Symbol: SaiLife

To BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400001 BSE Scrip Code: 544306

Sub: Investor Presentation for the quarter ended 30 June 2025.

Dear Sir/ Madam,

With reference to the above subject, we enclose herewith the Investor Presentation for the quarter ended 30 June 2025.

We request you to take note of the same and oblige.

Thank you.

For Sai Life Sciences Limited

Runa Karan Company Secretary & Compliance Officer Membership No.: A13721

Encl: As above

Sai Life Sciences Limited (CIN: L24110TG1999PLC030970)

Corporate office

Registered office

# L4-01 & 02, SLN Terminus, Survey #133, Gachibowli Miyapur Road, Gachibowli, Hyderabad – 500032, Telangana, India.

Plot No. DS-7, IKP Knowledge Park, Turkapally (V), Shameerpet Mandal, Medchal-Malkajgiri (Dist), Hyderabad -500078, Telangana, India.

Sai Life Sciences Limited

Investor Presentation

August 08, 2025

Safe Harbour

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include

words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate",

"intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar

expressions of such expressions may constitute "forward-looking statements", These forward looking statements involve a number of

risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking

statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth

and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income,

cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update

forward-looking statements to reflect events or circumstances after the date thereof.

The CRDMO industry is a Service Business with value drivers different from generic pharma companies

• R&D investments in drug discovery / development program translate to revenue opportunities for CRDMOs – irrespective of whether it receives approval or not

•

Stage-gating decisions rest with the innovator (clients)

• Given the multitude of factors involved, the success or failure of a molecule is never

directly attributed to the CRDMO.

• CRDMOs are purely judged by the quality of work they render within the scope of the

defined project

Sai Life Sciences is an Associate Member of ACS-Green

Chemistry Institute Pharmaceutical Roundtable

“ As a CRDMO, our value doesn’t hinge on drug approvals - we’re not in the business of binary outcomes. We generate consistent, scalable value through scientific depth, execution reliability, and long term client partnerships.

“

- Krishna Kanumuri, MD & CEO

Executive Summary

Message from Managing Director & CEO

“

We have begun FY26 on a strong footing, delivering healthy performance across our Discovery,

Development and Commercial Manufacturing businesses. This momentum reflects the growing trust and

deepening engagement we share with our global pharma clients' relationships that continue to anchor us

through macroeconomic uncertainty and broader industry cycles.

As the nature of innovation in drug development evolves, we are proactively investing in the infrastructure

and scientific depth required to support complex and emerging modalities. During the quarter, we

inaugurated new Biology Labs that significantly strengthen our Integrated Discovery platform and enhance

our ability to handle greater molecular complexity. We also broke ground on a new Process R&D Block at

our Hyderabad campus, which will nearly double our process R&D capacity and bring in next generation,

data-rich process capabilities to handle increasingly complex molecules.

These are deliberate steps in our journey to be the partner of choice for advancing innovation in complex

science. We remain committed to enabling our clients’ aspirations with speed, scientific rigor, and an

unrelenting focus on quality. “

Mr. Krishna Kanumuri

MD & CEO

Message from Chief Financial Officer

“

We are pleased to report a robust performance for Q1FY26, marked by strong growth across our Discovery and CDMO businesses.

Total revenue for the quarter stood at ₹496 Cr, up 77% YoY, led by 113% growth in CDMO and a 38% rise in Discovery, enabled by deeper engagement with global clients.

We recorded EBITDA of ₹125 Cr, growing 305% YoY, with margins expanding to 25%, an improvement of 14% YoY driven by operating leverage, scale efficiencies, and improved productivity across our sites.

During the quarter, we invested ₹134 Cr in capex. This includes investments in new R&D infrastructure and process development capabilities, enabling us to support complex and emerging modalities such as peptides, ADCs, and oligonucleotides.

As we look ahead, we remain optimistic about our growth trajectory. With a strong foundation in place, we are focused on scaling execution, strengthening client partnerships, and investing in technology and talent to deliver sustained performance and long-term value.

“

Mr. Siva Chittor

CFO

Q1FY26 Business Highlights

Infrastructure & Capacity Expansion

• Commenced commercial operations at Bidar (PB-11 Phase II), adding ~91 KL capacity and taking the total manufacturing capacity to ~700 KL

•

Inaugurated Peptide Research Center at Hyderabad R&D campus, strengthening capabilities in complex peptides and emerging modalities

Inaugurated 10,300 sq. ft. Biology facility with multiple laboratories, strengthening the company’s discovery offering.

• Construction underway for new Medicinal Chemistry block with 200 fume hood capacity

• Broke ground for a new Process R&D Block at Unit 2 Hyderabad, nearly doubling PRD capacity and adding capabilities in early phase peptide

development and Clinical Formulations

• Commencing work on building additional 200 KL production capacity at Unit IV, Bidar; to be ready by Q3FY27

• Onboarded 253 scientists and technical staff to support scaling

• Recognised as Great Place to Work

, strengthening talent positioning

Sustainability, Quality & Compliance

•

Launched GoGreen Plus logistics initiative with DHL for low-emission pharma shipments

• Completed 11 client and regulatory audits successfully across sites during Q1FY26

Consolidated Financial Highlights

Revenue (₹ Cr)

Material Margin (₹ Cr) and Margin (%)

EBITDA (₹ Cr) and Margin (%)

PAT (₹ Cr) and Margin (%)

496

280

72%

355

74%

207

25%

125

11%

12%

-13 -5%

Q1FY25

Q1FY26

Q1FY25

Q1FY26

Q1FY25

Q1FY26

Q1FY25

Q1FY26

Q1FY26 Revenue Contribution

CDMO

CRO

63%

37%

•

Revenue for Q1FY26 was ₹496 crore, a 77% increase over ₹280 crore in Q1FY25, driven primarily by strong growth in the CDMO

CDMO recorded revenues of ₹314 Cr in Q1FY26, up 113% from ₹148 Cr in Q1FY25

CRO recorded revenues of ₹182 Cr in Q1FY26, up 38% from ₹132 Cr in Q1FY25

EBITDA for Q1FY26 stood at ₹125 Cr compared to ₹31 Cr in Q1FY25, an increase of 305%

EBITDA margin expanded by 14% YoY to 25% in Q1FY26

PAT for Q1FY26 stood at ₹60 crore.

Invested ₹134 crore in capital expenditure during Q1FY26

Sustained Growth Momentum with Expanding Profitability

(Consolidated)

20%

1,465

25%

1,695

15%

1,217

870

25%

11%

496

280

Positioned to achieve 15-20% revenue CAGR over 3-5 years, 28 - 30% EBITDA margins over the next 2-3 years

FY22

FY23

FY24

FY25

Q1FY25

Q1FY26

IPO

Revenue (₹ Cr)

EBITDA Margin (%)

Delivered consistent revenue growth and expanding profitability, with EBITDA margins rising from 15% in FY22 to 25% by FY25 and maintaining positive momentum in Q1FY26, keeping Sai on track toward its longer-term growth aspirations

Company Overview

Sai Life Sciences: At a Glance

25+ Years of Expertise

Global Partner of Choice

Expansive Infrastructure

Innovation-Led Growth

Founded in 1999, Sai Life Sciences has transformed into an integrated CRDMO, delivering value across the pharma lifecycle from early discovery to commercial manufacturing

Trusted by 300+ global clients, including 18 of the top 25 global pharma companies across the US, UK, EU, and Japan

World-class R&D and manufacturing facilities across Hyderabad, Bidar, Manchester, and Boston, with ~700 KL of installed capacity

Focused investments in next- gen modalities like Peptides, ADCs, Oligos and TPDs; empowered by digital transformation, automation, and AI/ML to accelerate delivery and differentiation

Key Highlights

25+

Years of experience

(Incorporated in 1999)

One-stop platform for discovery, development and manufacturing

USFDA, PMDA

100% successful track record of

regulatory inspections across our R&D and manufacturing facilities.

Diverse therapy areas Oncology, CNS, Inflammation, Antivirals, Rare diseases and more

3,400+

Total employees

10+

Years: Enduring customer relationships

300+

Active customers across US, UK, EU, Japan

18/25

of the largest pharmaceutical companies are customers

>65%

Integrated Drug Discovery (IDD)

18 months

Demonstrated time from Hit to IND

Commercial molecules

Phase III/ pre-registration

40+

Programs advanced to IND or Phase I/II/III

Molecules from discovery to market

Global Presence

Research laboratories for discovery and development located near overseas innovation hubs in Greater Boston, US and Manchester, UK,

complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India

Sai Facilities Presence

700 KL GMP Manufacturing

Process R&D Lab in Alderley Park

Manchester

Boston

Exploratory Biology Lab in the Cambridge-Boston Life Sciences ecosystem

Bidar

Hyderabad

Global Delivery Model

13-acre Integrated R&D Campus in Genome Valley

Strategically located to combine innovation access, client proximity, and cost efficiency

Our Growth Journey

1999 - 2008

2009 – 2013

2014 – 2018

2019 – 2023

2024 – Present

Founding & Early Biotech Foray

CDMO Pivot

Consolidation of CDMO Capabilities

Globalization, Scaled-up Integrated CRDMO

Increasing Capacity & Strengthening New-Age Modalities

• Incorporated in 1999; began as a medicinal chemistry partner to US biotech firms

• Expanded into Process R&D and

small-scale manufacturing aligned with the needs of Biotechs clients

• First USFDA approval of Unit IV

• Cleared USFDA & PMDA audits

• Entered global markets: labs in

• Listed on NSE & BSE

• Expanded R&D (Unit II) to enable

at multiple sites

Manchester & Boston

large-scale pharma CDMO services

• Added 100 KL capacity at Unit IV

• Animal facility received AAALAC

accreditation

• Integrated Biology services;

• Commissioned Clean Room,

becoming end-to-end Discovery partner

Amidites, and HPAPI blocks at Unit IV

• Added >120 KL (PB-07) and

>170 KL (PB-08) blocks at Unit IV

• Strategic partnership with Schrödinger to enhance discovery science

• Continued regulatory track record and expansion of global footprint

• Construction underway for new MedChem block with 200 fume hood capacity

• Broke ground for a new Process R&D Block at Unit 2 Hyderabad, nearly doubling PRD capacity and adding capabilities in early phase peptide development and clinical formulations

• Commenced work on building additional 200kL production capacity at Unit IV, Bidar

A leading CRDMO with scaled operations across both verticals

Sai Life Sciences operates as both a CRO and a CDMO, offering an end-to-end platform for global pharmaceutical and biotech companies

Phase 1

DISCOVERY (CRO)

Phase 2

DEVELOPMENT (CRO & CDMO)

Phase 3

MANUFACTURING (CDMO)

• Medicinal Chemistry & Computational

• Process Development & Optimization

• API (Active Pharmaceutical Ingredient)

Drug Discovery

• Biology & Pharmacology Research

• Analytical Development & Validation

• Formulation Development & Stability

Manufacturing

• Technology Transfer & Scale-Up

• DMPK & Toxicology Studies

Studies

• Commercial Production & Global Supply

• Preclinical Research & IND Filing

• Clinical Trial Supplies (Phase I-III)

Chain

• Regulatory Compliance & Quality

Assurance

• Regulatory-Compliant Manufacturing

(US FDA, PMDA, COFEPRIS)

Seamless Integration – One-stop solution from research to commercial production

Regulatory Excellence – Compliant with global standards (US FDA, PMDA, COFEPRIS)

Scalable & Flexible – Supporting emerging biotech & leading pharma companies

Discovery Services (CRO)

Consistent Revenue Growth (₹ Cr)

626

467

497

274

189

FY21

FY22

FY23

FY24

FY25

Customer Split %

67%

62%

33%

FY24

38%

FY25

Pharma

Biotech

Client Stickiness

Dedicated Facility

Modalities Expansion

>65% Revenues from

Among the few CROs

Expanding capabilities

customers in FY23-25

with a dedicated facility

in ADCs, TPDs,

who availed more than

for a global innovator,

Peptides, CGTs, Oligos,

one Discovery services(2)

now scaled up by 30%

and more.

to support growing

demand and deeper

integration.

Notes: (1) Last 5 years (2) Discovery services (including chemistry, biology and/or DMPK services)

Discovery Services: Scaling Innovation, Driving Impact

>65% of Discovery programs are now integrated, with active use of next-gen biology, automation, and AI to accelerate development and improve outcomes

Expanded Core Capabilities

Colocalized & Global Teams

Tech-Enabled Drug Discovery

Specialized Modalities

Next-Gen Preclinical Models

Scaled Chemistry, Biology,

Hyderabad campus and

AI-enabled retrosynthesis

Peptides, ADC payloads,

Organoids and spheroids

DMPK, and In Vivo labs

Boston Biology Lab enable

tools High-throughput

Oligos, TPDs and driving

enable predictive, FDA-

delivering faster, parallelized

seamless collaboration and

Experimentation DMPK

high-value Discovery growth

aligned efficacy and toxicity

research

rapid tech transfer

automation CADD in silico

testing

tools

Technology advancements are transforming Sai’s Discovery platform into a scalable, high-value growth engine

CMC Services (CDMO)

Consistent Revenue Growth (₹ Cr)

•

End-to-End capabilities from IND through to commercialization

Focus on Complex Chemistry, ADC Payloads & Linkers

• Modern, GMP-compliant facilities across UK and India

571

596

760

968

1,068

•

Flexibility to support both small-scale clinical supplies and large-scale commercial production.

Proven track record of commercializing NCEs

• Robust regulatory record with USFDA and PMDA

•

160 Programs in the pipeline across multiple therapy areas

• Clear Regulatory Record: USFDA, PMDA

FY21

FY22

FY23

FY24

FY25

•

At the forefront of digitalization, automation and sustainability

Customer Split %

Business Mix Revenue Contribution – By Therapy (%)

21%

79%

91%

21%

18%

11%

22%

14%

12%

10%

17%

10%

FY24

FY25

Pharma

Biotech

CNS

Infectious Diseases

Cardiovascular Anti Histamine

Oncology

Metabolic Disorders

Genetic Disorders

Dermatology

Immunology

Others

FY24

FY25

Note: Therapy area contribution varies year-to-year based on client portfolio mix and project timelines. Not indicative of overall market trends

New Modalities: Fortifying foundation to build scale

New Modalities Revenue Contribution (%)

FY22

FY23

FY24

FY25

Peptides

Antibody-Drug Conjugates

Complement peptide discovery with process and scale-up facilities for clinical supplies; focus on commercial supply of fragments before evolving to full-scale peptide manufacturing.

Enhancing conjugation in Discovery; upgrading to class 6 containment for end-to-end support. Evaluating clinical conjugation and fill-finish for clinical supply

Oligonucleotides

Lipids

Involved in multiple projects with Pharma from development to commercial; to focus only on making amidites.

Involved in supplying lipids for last few years; looking to expand capacity

Our Strengths

Strategic Growth Levers & Competitive Edge

Expanding Capacity & Capabilities

Technology-Driven Efficiency

Talent & Innovation Culture

Deeper Customer Engagement

Global Footprint, Local Advantage

Quality & Sustainability Leadership

Information Technology - Driven Excellence: Digitization & Beyond

Digitization

2017 onwards

Digitalization

2022 onwards

Digital Transformation

2023 onwards

Converting data, documents and processes from paper/ analog to digital

Use of digitized data for effective monitoring through visual interactive dashboards.

integration of digital technologies into all aspects of business operations

R&D and Mfg processes progressively digitized to current levels of 85% digitization

Interactive Business Intelligence dashboards created using real-time data across functions and use cases.

Leveraging large data sets with AIML models to create prediction models.

• GMP Pro and ELN implementation • QR Code & Label Management • Learning Management System • Audit Management System • Laboratory Information Management System • Validation Life Cycle Management System

• Batch Quality, Yield, Experiments, Equipment

Occupancy, Staffing status, QMS, etc.

• Digital Transformation Initiatives • AI/ML - Manufacturing Process Prediction

Model

Looking Ahead

• • • •

Digitization process expected to be complete by 2027 Continued adoption of BI models to aid faster decision-making AI/ML model proof-of-concept outcome to emerge in 2025. Based on results, further integration into operations will be undertaken.

Global-Standard Operations, End-to-End

Quality Assurance

Sustainability Leadership

Safety & EHS Leadership

• 285+ QA/QC professionals

• 89% renewable energy at Bidar

• Embedded Process Safety from

across sites

site

• Integrated e-systems: LIMS, e-

• Zero Liquid Discharge: water-

QMS

neutral ops

• QA independent; reports to

• Carbon roadmap approved by

CEO

• Audited by USFDA, EMA, PMDA, Indian regulators

• Focus on data integrity & global

compliance

SBTi

• Low-emission logistics via DHL

quote to execution phase; rigorous lifecycle safety assessments.

• Plant Intermediates areas & lab fume cupboards validated down to 1 µcg/ m3 containment

• First Indian company to join the PSCI membership; >30 PSCI Audits over the past 7 years

• Silver rating by EcoVadis

Key Drivers for Growth

Scaling Capacity & Infrastructure

Diversifying Portfolio

Scientific & Talent Leadership

•

The company continue to make strategic capital investments in line with its annual capex plan of ~ ₹700 Cr for FY26 to enhance manufacturing and R&D infrastructure, including development of a second manufacturing site in Hyderabad.

These strategic investments will nearly double Sai’s overall manufacturing capacity by FY27, while diversifying its footprint and reducing concentration risk

•

36 active molecules* –30 commercial, with 6 Phase III / pre registration

160 in early phase development

Established model for a dedicated partnerships

Average tenure of large pharma relationships is ~10 years

200+ clients, 60+ integrated collaboration under discovery

•

Driving global program transfers to India across discovery, development & manufacturing

Rapidly expanding leadership bench with experts from top CDMOs and global pharma

Strengthening capabilities in new modalities, enabling pipeline expansion and stickier client relationships

Building future-ready teams aligned to Sai’s scale-up and innovation roadmap

* Excluding molecules under destocking and low value molecules with limited potential

Industry Overview

Global CRDMO Industry Set to Cross USD 300 Bn by 2028

Global CRDMO Market (USD Bn)

Global CRDMO Market by Modality (USD Bn)

303

196

127

225

Large molecule

Small molecule

153

106

2018

2023

2028E

2018

2023

2028E

• Global CRDMO market projected to reach USD 303 Bn by 2028 (9% CAGR 2023-2028)

•

50%+ of pharma R&D budgets outsourced to CRDMOs, driving structural growth

• Biologics, peptides, and oligonucleotides expected to drive ~40% of total growth by 2028

With growing investments

in biologics, peptides, and

new modalities, Sai Life

Sciences is positioned to

capture growth in the

fastest-expanding CRDMO

segments globally

•

Large molecule CRDMO segment growing fastest (12% CAGR 2023 - 28), supported by biologics demand

• Asia-Pacific market projected to grow at 12% CAGR (2023–28) - the fastest among all regions, outpacing Europe (10%) and North

America (5%)

Source: Frost & Sullivan

India Rising as a Strategic CRDMO Hub

Indian CRDMO Market (USD Bn)

Global CRDMO Market by Modality (USD Bn)

Large molecule

Small molecule

2018

2023

2028E

2018

2023

2028E

Sai Life Sciences is

scaling capacity,

innovation, and specialty

modalities to leverage

India’s rising global

CRDMO share and China-

to-India outsourcing shift.

•

Indian CRDMO industry is among the fastest-growing worldwide, projected to grow at 14% CAGR (2023–28)

• By 2028, CDMO is expected to contribute ~75% of India’s USD 14 Bn CRDMO market, growing to USD 11 Bn, while CRO expands to

USD 3 Bn

• Cost efficiency (30–40%) with global-standard quality is making India the preferred outsourcing destination for pharma sponsors

Source: Frost & Sullivan

Annexure

Consolidated Statement of Profit and Loss

Particulars (₹ Cr)

Revenue from operations

Other income

Total income

Expenses

Cost of materials consumed and changes in inventories

Employee benefits expense

Other expenses

Forex (gain)/loss

EBITDA

EBITDA Margin

Finance costs

Depreciation and amortisation expense

Profit before tax

Tax expense

Profit after tax

Q1FY26

Q1FY25

Q4FY25

496

506

141

161

(4)

125

25%

280

288

130

(5)

11%

-18

-5

-13

580

586

168

151

103

(3)

161

28%

119

FY25

1695

1712

466

549

274

(19)

425

25%

139

228

170

FY24

1465

1494

446

495

239

(15)

300

20%

119

109

Glossary

APIs

Biotechs

Active pharmaceutical ingredients

Biotechnology companies, often referred to as biotech companies, are largely startups in the pharmaceutical sector which typically focus on developing innovative drugs and drug development technologies to address unmet medical needs

Blockbuster End Molecules Blockbusters are drug products with annual sales of over US$1 billion in the Financial Year 2023

CDSCO

CMC / CDMO

CMO

Central Drug Standards Control Organization, India

Chemistry, Manufacturing and Control / Contract Development and Manufacturing Organization

Contract Manufacturing Organization

COFEPRIS Mexico

Federal Commission for the Protection against Sanitary Risk of Mexico

CRDMO

CRO

DMPK

GATT

Contract Research, Development, And Manufacturing Organization

Contract Research Organization

Drug metabolism and pharmacokinetics

General Agreement on Tariffs and Trade

Generic drugs

Refer to pharmaceutical drugs that have the same chemical composition as the original innovator drug and can be sold by companies after the patent on the original drug expires

Innovation Clusters/Hubs

Nine regions identified by Frost and Sullivan including Boston/Cambridge in Massachusetts, Manchester/London/Cambridge in UK, Chicago in Illinois, New Jersey, New York, Paris in France, Switzerland and Japan. In 2022, approximately 57% of global R&D spending were in these nine pharma hubs

Innovator Drugs

Refer to first drugs created containing specific active ingredients and undergo approval or patent process for use

Large Molecule

Have a large molecular weight and made of proteins that are complex in structure compared to small molecule drugs. Costly to manufacture and, at this time, in most cases can only be administered by injection or infusion. Typically manufactured biologically, i.e. extracted from living organisms, but often include certain synthetic chemistry processes

Large Pharma Companies

Pharma companies with revenues > USD 10 billion

Mid Pharma Companies

Pharma companies with revenues in range of USD 500 million to USD 10 billion

NCE

PMDA

Small Molecule

New chemical entities

Pharmaceuticals and Medical Devices Agency, Japan

Organic compound with low molecular weight, small molecule drugs are known for their affordability, ease of administration (largely orally), and broad therapeutic coverage. Typically manufactured using synthetic chemistry processes

Small Pharma Companies

Pharma companies with revenues lower than USD 500 million

TRIPS

UNIT IV

USFDA

Trade-Related Aspects of Intellectual Property Rights

Manufacturing facility at Bidar

United States Food and Drug Administration

Thank You

For more details please contact:

Investorrelation@sailife.com

L4, SLN Terminus, Gachibowli, Hyderabad 500032, Telangana, India.

← All Transcripts SAILIFE Stock Page →

Sai Life Sciences Limited has informed the Exchange about Investor Presentation

Market Movers